Development of a Novel Cell-Permeable Protein–Protein Interaction Inhibitor for the Polo-box Domain of Polo-like Kinase 1

[Image: see text] Polo-like kinase 1 (PLK1) is a key regulator of mitosis and a recognized drug target for cancer therapy. Inhibiting the polo-box domain of PLK1 offers potential advantages of increased selectivity and subsequently reduced toxicity compared with targeting the kinase domain. However,...

Descripción completa

Detalles Bibliográficos
Autores principales: Huggins, David J., Hardwick, Bryn S., Sharma, Pooja, Emery, Amy, Laraia, Luca, Zhang, Fengzhi, Narvaez, Ana J., Roberts-Thomson, Meredith, Crooks, Alex T., Boyle, Robert G., Boyce, Richard, Walker, David W., Mateu, Natalia, McKenzie, Grahame J., Spring, David R., Venkitaraman, Ashok R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2019
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964520/
https://www.ncbi.nlm.nih.gov/pubmed/31956833
http://dx.doi.org/10.1021/acsomega.9b03626

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964520/
https://www.ncbi.nlm.nih.gov/pubmed/31956833
http://dx.doi.org/10.1021/acsomega.9b03626

Ejemplares similares